Lung cancer Posts on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

Nivolumab in previously treated advanced non-small cell lung cancer – what is the long-term outlook for survival?

Posted by on Sep 16, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated survival rates in advanced non-small cell lung cancer (NSCLC) after nivolumab (Opdivo) treatment.  They found that nivolumab was associated with longer survival time in patients that responded to treatment.  Some background Lung cancer (LC) is one of the most common cancers worldwide. Non-small...

Read More

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Evaluating ALK tyrosine kinase inhibitor drugs for elderly patients with non-small cell lung cancer

Posted by on Sep 16, 2019 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of three different ALK tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC). The authors concluded that these inhibitors were similarly effective, but elderly patients over age 65 were more likely to develop side effects. Some background NSCLC is...

Read More

Looking for patients with advanced non-small cell lung cancer to test a biological therapy.

Posted by on Sep 10, 2019 in Lung cancer | 0 comments

In a nutshell This trial is examining the effectiveness of pegilodecakin (AM0010) when it is used with pembrolizumab (Keytruda) to treat patients with advanced non-small cell lung cancer (NSCLC). The main outcome to be measured will be tumor responses to the treatment. This trial is recruiting in multiple locations around the United States. The...

Read More

Can neutrophil to lymphocyte ratio guide treatment choice in small cell lung cancer?

Posted by on Sep 9, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated if neutrophil to lymphocyte ratio (NLR) can be used to chose a first-line treatment in patients with small-cell lung cancer (SCLC). They found that NLR could be used to choose a treatment for these patients. Some background Lung cancer is a common cancer with poor prognosis. Small cell lung cancer (SCLC) is a...

Read More

Searching for patients with advanced non-small cell lung cancer to test a new combination therapy

Posted by on Aug 22, 2019 in Lung cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In...

Read More

Chemoradiotherapy versus radiation only – which is more effective in inoperable lung cancer?

Posted by on Aug 17, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness of radiation therapy (RT) and chemoradiotherapy (CRT) in inoperable non-small cell lung cancer (NSCLC). They found that CRT was more effective than RT alone in these patients.  Some background Non-small cell lung cancer (NSCLC) is the most common form of lung cancer (LC)....

Read More

Looking for participants with metastatic non-small cell lung cancer to test a new immunotherapy

Posted by on Aug 14, 2019 in Lung cancer | 0 comments

In a nutshell This phase 1 trial is examining the effectiveness of personalized tumor antigens (PTA) in the treatment of different advanced tumors. The main outcomes to be measured will be side effects and disease control. This study is being conducted in Arizona, California, Louisiana and New Jersey, US. The details While the tumor cells are growing,...

Read More

Evaluating long-term outcomes for stereotactic ablative body radiotherapy for early-stage non-small cell lung cancer.

Posted by on Aug 13, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if using stereotactic ablative body radiotherapy (SABR) improves survival in patients with early-stage non-small cell lung cancer (NSCLC). The study found that this treatment resulted in good long-term survival and had few side effects. Some background Stereotactic ablative body radiotherapy (SABR) is...

Read More

Searching patients with relapsed or unresponsive cancer to test a new medication

Posted by on Jul 31, 2019 in Lung cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of RMC-4630 and cobimetinib (Cotellic) in relapsed or unresponsive solid tumors.  The main outcomes will be the number of side effects and the overall response rate. This trial is recruiting in a number of US states.  The details Relapsed/refractory (R/R) cancer is a term for...

Read More

Concurrent vs. sequential – which is the best chemoradiotherapy strategy for non-small cell lung cancer?

Posted by on Jul 26, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated if concurrent (cCRT) or sequential chemoradiotherapy (sCRT) was more effective in non-small cell lung cancer (NSCLC). They found that sCRT was associated with better survival than cCRT. Some background Non-small cell lung cancer (NSCLC) is a common cancer. It is usually diagnosed at an advanced stage. Standard...

Read More